The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniramine buclizine carbinoxamine carebastine cetirizine chlorcyclizine chlorpheniramine cinnarizine clemastine clemizole clocinizine clonidine cyclizine cyproheptadine descarboethoxyloratidine dexchlorpheniramine dimenhydrinate dimethindene dimethothiazine diphenhydramine diphenylpyraline doxylamine ebastine efletirizine epinastine fexofenadine hydroxyzine ketotifen levocabastine loratidine meclizine mequitazine methdilazine mianserin mizolastine niaprazine noberastine norastemizole oxatomide oxomemazine phenbenzamine pheniramine picumast promethazine pyrilamine temelastine terfenadine trimeprazine tripelennamine triprolidine ranitidine cimetidine famotidine nizatidine tiotidine zolantidine ritanserine and derivatives thereof and mixtures of any two or more of the foregoing.

暂无附图